Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705793 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1146478 | 0.83 | ALDH1A1 (0.36) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL12348921 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL7753817 | 0.78 | THRB (0.44) | LMNA | |
| SCHEMBL7928503 | 0.75 | THRB (0.42) | LMNA | |
| SCHEMBL7937409 | 0.75 | THRB (0.42) | LMNA | |
| SCHEMBL8431364 | 0.75 | THRB (0.42) | LMNA | |
| SCHEMBL7937407 | 0.75 | THRB (0.42) | LMNA | |
| SCHEMBL7936833 | 0.75 | THRB (0.42) | LMNA | |
| SCHEMBL12759165 | 0.74 | THRB (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | SMN1; SMN2 4440/4885LMNA 2239/4885ALDH1A1 616/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | SMN1; SMN2 4440/4885LMNA 2239/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.